Armata Pharmaceuticals, Inc. (ARMP)
Automate Your Wheel Strategy on ARMP
With Tiblio's Option Bot, you can configure your own wheel strategy including ARMP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ARMP
- Rev/Share 0.0341
- Book/Share -1.4863
- PB -1.7223
- Debt/Equity -1.9888
- CurrentRatio 0.1191
- ROIC -0.2047
- MktCap 92655360.0
- FreeCF/Share -1.0025
- PFCF -2.5542
- PE -217.4486
- Debt/Assets 1.2259
- DivYield 0
- ROE 0.0086
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
ARMP Soars 72% in a Month Following Infectious Disease Study Success
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Armata Pharmaceuticals stock surges 72% in a month following superior efficacy results from a phase Ib/IIa study of AP-SA02 for treating an infectious disease.
Read More
Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia
Published: May 19, 2025 by: PRNewsWire
Sentiment: Neutral
All primary endpoints for safety, tolerability, and clinical response in the intent-to-treat population met AP-SA02 arm significantly improved clinical outcomes and prevented relapse compared to best available antibiotic therapy No treatment-related serious adverse events were observed with repetitive intravenous dosing LOS ANGELES , May 19, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced positive topline results from its Phase 1b/2a diSArm trial which evaluated AP-SA02, a novel intravenous ("IV") administered multi-phage …
Read More
New Strong Sell Stocks for May 8th
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Negative
ARMP, COLM and EFSI have been added to the Zacks Rank #5 (Strong Sell) List on May 8, 2025.
Read More
Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02
Published: May 01, 2025 by: PRNewsWire
Sentiment: Neutral
Phase 1b/2a diSArm trial evaluated AP-SA02 as a potential treatment for complicated Staphylococcus aureus bacteremia Topline data anticipated in Q2 2025 to support potential future pivotal bacteremia efficacy trial LOS ANGELES , May 1, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has received an additional $4.65 million of non-dilutive funding pursuant to a previously announced Department of Defense (DoD) award, received through the Medical Technology Enterprise Consortium (MTEC) and …
Read More
New Strong Sell Stocks for April 28th
Published: April 28, 2025 by: Zacks Investment Research
Sentiment: Negative
CCS, ARMP and CABO have been added to the Zacks Rank #5 (Strong Sell) List on April 28, 2025.
Read More
About Armata Pharmaceuticals, Inc. (ARMP)
- IPO Date 1994-05-20
- Website https://www.armatapharma.com
- Industry Biotechnology
- CEO Deborah L. Birx
- Employees 60